Inceptionr LLC Makes New Investment in Corcept Therapeutics Incorporated $CORT

Posted by Brian Himes on Jul 28th, 2026

Inceptionr LLC purchased a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,612 shares of the biotechnology company’s stock, valued at approximately $347,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CORT. Royal Bank of Canada lifted its stake in shares of Corcept Therapeutics by 18.9% in the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after acquiring an additional 2,444 shares during the last quarter. Amundi bought a new position in Corcept Therapeutics during the 1st quarter worth approximately $450,000. NewEdge Advisors LLC bought a new position in Corcept Therapeutics during the 1st quarter worth approximately $518,000. EverSource Wealth Advisors LLC increased its stake in Corcept Therapeutics by 273.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 1,055 shares during the period. Finally, Marshall Wace LLP increased its stake in Corcept Therapeutics by 795.3% in the 2nd quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 41,040 shares during the period. 93.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

CORT has been the subject of a number of analyst reports. Piper Sandler increased their price objective on Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. HC Wainwright lifted their target price on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Wolfe Research reiterated an “underperform” rating and set a $50.00 price target on shares of Corcept Therapeutics in a report on Monday. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $92.17.

Get Our Latest Research Report on Corcept Therapeutics

Corcept Therapeutics Price Performance

CORT opened at $91.12 on Tuesday. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $97.63. The business has a 50 day simple moving average of $81.12 and a two-hundred day simple moving average of $55.00. The firm has a market capitalization of $9.78 billion, a price-to-earnings ratio of 260.35 and a beta of 0.47.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. During the same quarter in the prior year, the business posted $0.17 earnings per share. Corcept Therapeutics’s quarterly revenue was up 4.9% compared to the same quarter last year. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling

In other Corcept Therapeutics news, Director David L. Mahoney sold 20,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the transaction, the director directly owned 26,147 shares of the company’s stock, valued at approximately $2,210,205.91. The trade was a 43.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Atabak Mokari sold 40,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $81.15, for a total transaction of $3,246,000.00. Following the completion of the transaction, the chief financial officer owned 16,130 shares of the company’s stock, valued at $1,308,949.50. This trade represents a 71.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 300,000 shares of company stock valued at $22,088,050 over the last three months. Insiders own 20.70% of the company’s stock.

Corcept Therapeutics Company Profile

(Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.